The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
 
Xicheng Wang
No Relationships to Disclose
 
Yanhong Deng
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Xianglin Yuan
No Relationships to Disclose
 
Jianwei Yang
No Relationships to Disclose
 
Tao Zhang
No Relationships to Disclose
 
Ai-min Zang
No Relationships to Disclose
 
Yu Liu
No Relationships to Disclose
 
Li Huang
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Hong Zong
No Relationships to Disclose
 
Yi Ba
No Relationships to Disclose
 
Isabelle Klauck
Employment - Pierre Fabre Laboratories
 
Jean-Claude Vedovato
Employment - Pierre Fabre Laboratories
 
Melanie Groc
Employment - Pierre Fabre Laboratories
 
Angela Guo
Employment - Pierre Fabre Laboratories
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)